**Author’s response to reviews**

**Title:** Tamoxifen Use reduces Osteoporotic Fracture Risk in Asia Breast cancer woman: A nationwide population-based cohort study

**Authors:**

Huey-En Tzeng (tzenghueyen@gmail.com)
Chih-Hsin Muo (a17776@mail.cmuh.org.tw)
Hsien-Te Chen (bonekid1@gmail.com)
Wen-Li Hwang (kevinhwil@gmail.com)
Horng-Chang Hsu (D4749@mail.cmuh.org.tw)
Chun-Hao Tsai (ritsai8615@gmail.com)

**Version:** 2  **Date:** 3 February 2015

**Author’s response to reviews:**

For dear editor:

Fracture is the most serious event in the musculoskeletal events associated with the management of endocrine-responsive breast cancer. However, there remains controversy as to whether tamoxifen significantly reduces fracture rates in different age groups in the related literature. Therefore, we conducted this nationwide population-based database of a universal insurance program to evaluate whether tamoxifen offer a protective effect with regards to fracture risk in Asian breast cancer women should be investigated among those whose major peak age is 10 year-old younger than the Western. We would like to submit this manuscript entitled " Tamoxifen Use reduces Osteoporotic Fracture Risk in Asia Breast cancer woman: A nationwide population-based cohort study " by Huey-En Tzeng ,ect, for publication in “BMC Cancer”. The manuscript, as submitted or its essence in another version, is not under consideration for publication elsewhere, and will not be published elsewhere while under consideration by “BMC Cancer”. The authors have no commercial associations or sources of support that might pose a conflict of interest. All authors have made substantive contributions to the study, and all authors endorse the data and conclusions.

We certify that the work has not been published or submitted elsewhere for review. All authors have read and approved the manuscript. No conflict of interest exists with this research.

We look forward to your kind review of this manuscript. Correspondence can be addressed to the author listed above. Thanks for your consideration, and we look forward to receiving your reply comments.

Sincerely

Chun-Hao Tsai, MD

Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan, #91 Hsueh-Shih Road, Taichung 404, Taiwan.
E-mail: ritsai8615@gmail.com
Tel.: +886-4-2205-3366 ext. 6505; Fax: +886-4-2207-0429